Journal article icon

Journal article

From Pan-T-Cell Depletion to Selective Graft Engineering: Progress, Limitations, and Open Questions

Abstract:
The success of allogeneic haematopoietic stem cell transplantation is limited by three linked problems: graft-versus-host disease (GVHD), relapse, and infection. Pan-T-cell depletion, introduced in the 1980s, controlled GVHD but at the cost of relapse and impaired immune reconstitution. This trade-off has driven the field toward selective graft engineering, manipulating the donor graft’s cellular composition to separate GVHD-causing cells from those responsible for graft-versus-leukaemia (GVL) activity and infection control. This review traces that evolution, from CD34+ selection through αβ/CD19 depletion, naïve (CD45RA+) T-cell depletion, adoptive add-back, and gene-edited donor grafts, evaluated against current in vivo prophylaxis, principally post-transplant cyclophosphamide (PTCy). Selective graft-engineering platforms have achieved low rates of chronic GVHD and non-relapse mortality in defined settings. More recently, TREGZI (developed as Orca-T) received U.S. Food and Drug Administration (FDA) approval in June 2026 for adults with haematological malignancies undergoing matched-donor myeloablative allo-HSCT, following a randomised phase III trial against tacrolimus/methotrexate rather than PTCy. However, evidence for most other platforms remains dominated by single-arm, paediatric, or single-centre series; adult data are sparse, and no randomised trial has directly compared ex vivo graft engineering with optimised PTCy-based prophylaxis. Manufacturing infrastructure, cost, and access further limit adoption relative to established prophylaxis. Randomised trials are needed to determine whether, and for which patients, selective graft engineering offers a survival advantage.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.3390/jcm15218407

Authors

More by this author
Institution:
University of Oxford
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Radcliffe Department of Medicine
Sub department:
RDM-Strategic
Role:
Author
ORCID:
0000-0001-7722-3956


Publisher:
MDPI
Journal:
Journal of Clinical Medicine More from this journal
Volume:
15
Issue:
21
Pages:
8407-8407
Publication date:
2026-10-28
Acceptance date:
2026-10-16
DOI:
EISSN:
2077-0383
ISSN:
2077-0383


Language:
English
Keywords:
Pubs id:
2497211
Local pid:
pubs:2497211
Source identifiers:
W7224116659
Deposit date:
2026-11-20
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads

Views and downloads will return soon






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP